188 related articles for article (PubMed ID: 19210288)
21. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease.
Weiss KH; Gotthardt DN; Klemm D; Merle U; Ferenci-Foerster D; Schaefer M; Ferenci P; Stremmel W
Gastroenterology; 2011 Apr; 140(4):1189-1198.e1. PubMed ID: 21185835
[TBL] [Abstract][Full Text] [Related]
22. Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting.
Moores A; Fox S; Lang A; Hirschfield GM
Can J Gastroenterol; 2012 Jun; 26(6):333-9. PubMed ID: 22720274
[TBL] [Abstract][Full Text] [Related]
23. [Diagnosis and care of Wilson disease with neurological revelation].
Wagner S; Brunet AS; Bost M; Lachaux A; Broussolle E; Des Portes V; Lion-François L
Arch Pediatr; 2012 Mar; 19(3):271-6. PubMed ID: 22261259
[TBL] [Abstract][Full Text] [Related]
24. Wilson disease: genetic basis of copper toxicity and natural history.
Schilsky ML
Semin Liver Dis; 1996 Feb; 16(1):83-95. PubMed ID: 8723326
[TBL] [Abstract][Full Text] [Related]
25. Penicillamine-induced Elastosis Perforans Serpiginosa in Wilson Disease: Is Useful Switching to Zinc?
Ranucci G; Di Dato F; Leone F; Vajro P; Spagnuolo MI; Iorio R
J Pediatr Gastroenterol Nutr; 2017 Mar; 64(3):e72-e73. PubMed ID: 25341025
[No Abstract] [Full Text] [Related]
26. [Wilson disease in 2003].
Szalay F
Orv Hetil; 2003 Dec; 144(50):2451-8. PubMed ID: 15067983
[TBL] [Abstract][Full Text] [Related]
27. [Wilson disease].
Shimizu N
Nihon Rinsho; 2004 Jan; 62 Suppl():399-403. PubMed ID: 15011394
[No Abstract] [Full Text] [Related]
28. Boy with Dysarthria and Frequent Falls: A Treatable Disorder.
Sharawat IK; Kurup A; Sondhi V; Saini L
J Pediatr; 2019 Dec; 215():280-280.e1. PubMed ID: 31377039
[No Abstract] [Full Text] [Related]
29. Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease.
Kazemi K; Geramizadeh B; Nikeghbalian S; Salahi H; Bahador A; Reza Nejatollahi SM; Dehghani SM; Dehghani M; Kakaei F; Malek-Hosseini SA
Exp Clin Transplant; 2008 Dec; 6(4):261-3. PubMed ID: 19338486
[TBL] [Abstract][Full Text] [Related]
30. Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism.
Shimizu N; Fujiwara J; Ohnishi S; Sato M; Kodama H; Kohsaka T; Inui A; Fujisawa T; Tamai H; Ida S; Itoh S; Ito M; Horiike N; Harada M; Yoshino M; Aoki T
Transl Res; 2010 Dec; 156(6):350-7. PubMed ID: 21078496
[TBL] [Abstract][Full Text] [Related]
31. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature.
Taylor RM; Chen Y; Dhawan A;
Eur J Pediatr; 2009 Sep; 168(9):1061-8. PubMed ID: 19066958
[TBL] [Abstract][Full Text] [Related]
32. Metal element excretion in 24-h urine in patients with Wilson disease under treatment of D-penicillamine.
Huang L; Yu X; Zhang J; Liu X; Zhang Y; Jiao X; Yu X
Biol Trace Elem Res; 2012 May; 146(2):154-9. PubMed ID: 22076732
[TBL] [Abstract][Full Text] [Related]
33. Advances in Treatment of Wilson Disease.
Aggarwal A; Bhatt M
Tremor Other Hyperkinet Mov (N Y); 2018; 8():525. PubMed ID: 29520330
[TBL] [Abstract][Full Text] [Related]
34. Zinc monotherapy for young children with presymptomatic Wilson disease: A multicenter study in Japan.
Eda K; Mizuochi T; Iwama I; Inui A; Etani Y; Araki M; Hara S; Kumagai H; Hagiwara SI; Murayama K; Murakami J; Shimizu N; Kodama H; Yasuda R; Takaki Y; Yamashita Y
J Gastroenterol Hepatol; 2018 Jan; 33(1):264-269. PubMed ID: 28452067
[TBL] [Abstract][Full Text] [Related]
35. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
36. Recovery of severe acute liver failure without transplantation in patients with Wilson disease.
Kido J; Matsumoto S; Sakamoto R; Mitsubuchi H; Inomata Y; Nakamura K
Pediatr Transplant; 2018 Dec; 22(8):e13292. PubMed ID: 30368998
[TBL] [Abstract][Full Text] [Related]
37. Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.
Hou H; Chen D; Liu J; Feng L; Zhang J; Liang X; Xu Y; Li X
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101623. PubMed ID: 33662781
[TBL] [Abstract][Full Text] [Related]
38. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit.
El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M
Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.
Brewer GJ; Johnson V; Dick RD; Kluin KJ; Fink JK; Brunberg JA
Arch Neurol; 1996 Oct; 53(10):1017-25. PubMed ID: 8859064
[TBL] [Abstract][Full Text] [Related]
40. Pregnancy outcome after chelation therapy in Wilson disease. Evaluation of the German Embryotox Database.
Dathe K; Beck E; Schaefer C
Reprod Toxicol; 2016 Oct; 65():39-45. PubMed ID: 27350316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
